Narcolepsy is a sleep disorder caused by the selective death of orexin neurons that commonly occurs in childhood. Orexin neuron loss disinhibits REM sleep during the active period and produces cataplexy, an abnormal behavioral state between REM sleep and wake. Cataplexy is much more severe in children who develop narcolepsy than in adults, but the underlying mechanisms remain unknown. Histamine is a wake-promoting neuromodulator produced solely in the tuberomammillary nucleus. Histamine neurons are active during cataplexy, possibly maintaining consciousness during this REM sleep-like state. Mice lacking both orexins and histamine exhibit far less cataplexy than mice lacking only orexins, suggesting that histamine is necessary for cataplexy. In children with narcolepsy, cerebrospinal fluid histamine levels are higher than in healthy controls, whereas histamine levels are normal or low in adults with narcolepsy. Our pilot data indicate that orexin neuron loss in mice at age 4 weeks (young-onset) results in very severe cataplexy, whereas orexin neuron loss at age 14 weeks (adult-onset) results in little cataplexy but more REM sleep. We hypothesize that the abundant cataplexy in young mice is caused by a compensatory increase in histamine signaling. We will test this hypothesis by first analyzing sleep-wake behavior in young-onset and adult-onset mice acutely and chronically after orexin neuron loss to confirm that young-onset mice experience more cataplexy. Then, we will use photometry to measure histamine neuron activity during cataplexy and across sleep/wake states in young-onset mice to confirm whether histamine neurons are active during cataplexy. Finally, we will chemogenetically inhibit or activate histamine neurons to test whether elevated histamine neuron activity promotes cataplexy. These experiments will define the role of histamine neurons in the regulation of cataplexy in mice with young-onset or adult-onset orexin neuron loss. Ultimately, elucidating this mechanism of severe cataplexy should enable more targeted treatments for children with narcolepsy.

Public Health Relevance

Narcolepsy is a common sleep disorder that usually begins in childhood, and symptoms, especially cataplexy, are often more severe in children for unknown reasons. These experiments will use a novel mouse model to contrast young vs adult narcolepsy onset and examine the underlying mechanism. These findings will help determine why symptoms are more severe in children and provide new opportunities for better treating narcolepsy in children and adults.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Postdoctoral Individual National Research Service Award (F32)
Project #
5F32HD101193-02
Application #
10086329
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Lee, Karen
Project Start
2020-01-17
Project End
2021-04-16
Budget Start
2021-01-17
Budget End
2021-04-16
Support Year
2
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code